Master Protocol to Assess the Safety and Antitumour Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumours

Official Title

Master Protocol to Assess the Safety and Antitumour Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumours (IGNYTE-ESO)

Summary:

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumours.

Trial Description

Primary Outcome:

  • Substudy 1: Overall response rate (ORR)
  • Substudy 2: Overall response rate (ORR)
Secondary Outcome:
  • Substudy 1 and 2: Time to response
  • Substudy 1 and 2: Duration of response (DOR)
  • Substudy 1 and 2: Disease control rate (DCR)
  • Substudy 1 and 2: Progression free survival (PFS)
  • Substudy 1 and 2: Frequency of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) according to severity
  • Substudy 1 and 2: Number of participants with replication competent lentivirus (RCL)
  • Substudy 1 and 2: Number of participants with insertional oncogenesis (IO)
  • Substudy 2: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis parameters
  • Substudy 1 and 2: Maximum transgene expansion (Cmax) of letetresgene autoleucel
  • Substudy 1 and 2: Time to Cmax (Tmax)
  • Substudy 1 and 2: Area under the concentration/persistence time curve from zero to time t (AUC[0-t])
  • Substudy 2: Overall response rate (ORR)
  • Substudy 2: Overall Survival (OS)
  • Substudy 2: Number of participants with positive anti-drug antibodies (ADA) and titers of ADA against letetresgene autoleucel
New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumour-associated proteins that have been found in several tumour types. Clinical trials using adoptively transferred T cells directed against NY-ESO-1/LAGE-1a have shown objective responses. Letetresgene autoleucel (lete-cel, GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor engineered T cells. This is a master protocol investigating T-cell therapies. It will initially consist of a core protocol with two independent substudies investigating Letestresgene autoleucel in previously untreated (1L) Human Leukocyte Antigen (HLA)-A*02+ participants with NY-ESO-1+ advanced (metastatic or unresectable) synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS) (Substudy 1) and Letestresgene autoleucel as second line or higher (2L+) treatment in HLA-A*02+ participants with NY-ESO-1+ advanced (metastatic or unresectable) SS or MRCLS who have progressed following treatment with anthracycline based chemotherapy (Substudy 2).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society